Therefore, therapeutic targeting of MALT1 protease activity is a potential approach for the treatment of lymphomas or as an effective strategy for treating those neoplastic and inflammatory disorders which associated with dysregulated NF-κB signaling [23]. This evidence concerns the gene NFKB1 and lymphoma.